Provided by Tiger Trade Technology Pte. Ltd.

ProShares Ultra Health Care

57.82
+0.77171.35%
Post-market: 57.82-0.00170.00%19:30 EDT
Volume:4K
Turnover:235.03K
Market Cap:93.67M
PE:- -
High:57.82
Open:56.69
Low:56.69
Close:57.05
52wk High:64.60
52wk Low:42.76
Shares:1.62M
Float Shares:1.62M
Volume Ratio:0.17
T/O Rate:0.25%
Dividend:0.63
Dividend Rate:1.10%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

J&J - Tremfya Meets Primary Endpoint for Basdai Score Improvement at Week 24

THOMSON REUTERS
·
Sep 25

J&J - Tremfya Meets Primary and Major Secondary Endpoints in Axial Psa Study

THOMSON REUTERS
·
Sep 25

Johnson & Johnson Announces Tremfya® (Guselkumab) is the First and Only Il-23 Inhibitor to Show Significant Improvement in Spinal Pain and Stiffness in Landmark Axial Psoriatic Arthritis (Psa) Study

THOMSON REUTERS
·
Sep 25

Single Infusion of Carvykti Delivered Five-Year Treatment-Free Remissions in 50% of Patients in Early Line Relapsed/Refractory Multiple Myeloma

Reuters
·
Sep 25

Nektar Therapeutics - Jury Finds Lilly Breached Implied Covenant of Good Faith in License Agreement - SEC Filing

THOMSON REUTERS
·
Sep 25

J&J - Carvykti Delivers Five-Year Treatment-Free Remissions in 50% of Early Line Rrmm Patients

THOMSON REUTERS
·
Sep 25

J&J - Five-Year Overall Survival Rate 69.2%, Median Progression-Free Survival 60.5 Months

THOMSON REUTERS
·
Sep 25

FDA Approves Merck’s Welireg Plus Eisai’s Lenvima for Previously Treated Advanced Clear Cell Kidney Cancer

Reuters
·
Sep 25

Surrozen price target raised to $54 from $44 at H.C. Wainwright

TIPRANKS
·
Sep 25

Estee Lauder Cos. Cl a Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 25

Nanobiotix advances cancer nanotherapeutics and bolsters cash runway into 2029

TIPRANKS
·
Sep 25

France's Nanobiotix H1 Net Loss Widens on Lower Revenue, Absence of 2025 One-Off Gain

Reuters
·
Sep 25

Press Release: Nanobiotix Provides First Half 2026 Operational and Financial Update

Dow Jones
·
Sep 25

FDA approves Welireg and Lenvima combo for ccRCC

TIPRANKS
·
Sep 25

Merck Shares Flat in Volume Spike After FDA Approves Kidney Drug, Last up 0.50% at $148.81

THOMSON REUTERS
·
Sep 25

FDA Approves Belzutifan in Combination with Lenvatinib for Advanced Renal Cell Carcinoma with a Clear Cell Component

THOMSON REUTERS
·
Sep 25

Merck Has Two Overlooked Pipeline Catalysts Coming Before Year-End, UBS Says

MT Newswires Live
·
Sep 25

Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says

MT Newswires Live
·
Sep 25

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Reuters
·
Sep 25

Eli Lilly and Co Stock (LLY) Moved Up by 3.73% on Sep 24: A Full Analysis

TradingKey
·
Sep 24